Roche unveils its breakthrough proprietary SBX technology
Roche (RHHBY) unveiled its proprietary, breakthrough sequencing by expansion technology, establishing a new category of next-generation ...
Reuters2d
Roche Holding AG
Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback program ...
USA News Group: FDA Approval Race: AI-Powered Innovations Reshape the Healthcare Landscape
USA News Group News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, Feb. 11, 2025 /PRNewswire/ -- USA News Group News Commentary - Weeks after the monumental ...
Pharmabiz14d
Roche’s Susvimo receives US FDA approval for the treatment of diabetic macular edema
Roche announced that the US Food and Drug Administration (FDA) has approved Susvimo (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema (DME), a leading cause of vision loss ...
BioPharma Dive14d
Eli Lilly’s earnings, shares lifted by obesity drug sales
Eli Lilly’s profit doubled in the fourth quarter as the Indianapolis-based drugmaker raked in revenue from diabetes and obesity drugs. Net income rose to $4.4 billion, or $4.88 a share, from $2.2 ...
Newsday15d
Patients using diabetes apps can miss critical alerts. Here's how to make sure you're getting them
WASHINGTON — Patients who use smartphone apps to manage their diabetes could face serious health problems if they miss notifications needed to control their blood sugar, U.S. health officials ...
Genentech : FDA Approves Susvimo For Diabetic Macular Edema Treatment
Genentech, a member of the Roche Group (RHHBY), announced that the U.S. Food and Drug Administration has approved Susvimo ...
PharmiWeb15d
FDA approves Roche’s Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness
“Susvimo presents a unique, convenient treatment alternative to routine eye injections for people with a potentially blinding diabetic eye condition,” said Levi Garraway, MD, PhD, Roche's Chief ...
ENDPOINTS NEWS16d
J&J asks court for quick de­ci­sion in 340B re­bate mod­el fight
John­son & John­son has asked a fed­er­al dis­trict court to ex­pe­dite its de­ci­sion in a case over the com­pa­ny’s pro­posed 340B re­bate mod­el, cit­ing up­com­ing … ...
MarketWatch16d
Roche: FDA Approves Susvimo for Treatment of Diabetic Macular Edema
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...
Nasdaq16d
FDA approves Roche’s Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness
“Susvimo presents a unique, convenient treatment alternative to routine eye injections for people with a potentially blinding diabetic eye condition,” said Levi Garraway, MD, PhD, Roche's ...
FiercePharma16d
Roche gains label expansion for eye implant Susvimo to treat diabetic macular edema
Seven months after the FDA signed off on a reintroduction of Roche’s eye implant Susvimo, the U.S. regulator has broadened its label as a treatment for diabetic macular edema (DME), which is the ...